Our technology and applications enable improved targeting of complex treatments to the cancer patients who need them most. Scientific leaders at Yale and Caltech developed the IsoPlexis precision engineering platform to detect the full (omic) set of functions from thousands of single patient cells. This unprecedented quantity and quality of data from single cells is providing breakthrough clinical biomarker insights into highly urgent areas of oncology today.
IsoPlexis and Kite Pharma research offers hope for targeted CAR-T treatment...
The IsoPlexis IsoCode readout captures the omic end function from thousands of single cells in parallel to better understand complex patient response. The IsoCode chip, recognized in the literature as the SCBC, has been well validated in various immune and cancer detection applications, and has been making breakthroughs with UCLA, Memorial Sloan Kettering, and more.
Precision biomarker solutions in oncology areas of high complexity and high need